ReviewPharmaceutics2019
The Digital Pharmacies Era: How 3D Printing Technology Using Fused Deposition Modeling Can Become a Reality.
Review in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing.Pharmaceutics · 2026Review
- Innovative applications of 3D printing in personalized medicine and complex drug delivery systems.iScience · 2025Review
- Advancements in 3D printing technologies for personalized treatment of osteonecrosis of the femoral head.Materials today. Bio · 2025Review
- The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals.Pharmaceutics · 2025Review
- Personalized Kirigami Strain Sensors for in vivo Applications.Advanced intelligent systems (Weinheim an der Bergstrasse, Germany) · 2025Article
- Stability of Dexamethasone during Hot-Melt Extrusion of Filaments based on Eudragit® RS, Ethyl Cellulose and Polyethylene Oxide.International journal of pharmaceutics: X · 2024Article
- Article
- Fabrication of Polypill Pharmaceutical Dosage Forms Using Fused Deposition Modeling 3D Printing: A Systematic Review.Pharmaceutics · 2024Review
- Three-Dimensional Printing of PVA Capsular Devices for Applications in Compounding Pharmacy: Effect of Design Parameters on Pharmaceutical Performance.Pharmaceutics · 2024Article
- Trend of pharmaceuticals 3D printing in the Middle East and North Africa (MENA) region: An overview, regulatory perspective and future outlook.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Clopidogrel-loaded vascular grafts prepared using digital light processing 3D printing.Drug delivery and translational research · 2024Article
- 3D printing processes in precise drug delivery for personalized medicine.Biofabrication · 2024Review
- Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery.Drug delivery and translational research · 2024Article
- Impact of polymer chemistry on critical quality attributes of selective laser sintering 3D printed solid oral dosage forms.International journal of pharmaceutics: X · 2023Article
- 3D printing of amorphous solid dispersions: A comparison of fused deposition modeling and drop-on-powder printing.International journal of pharmaceutics: X · 2023Article
- Three-Dimensionally Printed Vaginal Rings: Perceptions of Women and Gynecologists in a Cross-Sectional Survey.Pharmaceutics · 2023Article
- Practical Application of 3D Printing for Pharmaceuticals in Hospitals and Pharmacies.Pharmaceutics · 2023Review
- Microbial Polysaccharide-Based Formulation with Silica Nanoparticles; A New Hydrogel Nanocomposite for 3D Printing.Gels (Basel, Switzerland) · 2023Article
- Mass Customization of Polylactic Acid (PLA) Parts via a Hybrid Manufacturing Process.Polymers · 2022Article
- Expanding Quality by Design Principles to Support 3D Printed Medical Device Development Following the Renewed Regulatory Framework in Europe.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmaceutical industry is set to join the fourth industrial revolution with the 3D printing of medicines. The application of 3D printers in compounding pharmacies will turn them into digital pharmacies, wrapping up the telemedicine care cycle and definitively modifying the pharmacotherapeutic treatment of patients. Fused deposition modeling 3D printing technology melts extruded drug-loaded filaments into any dosage form; and allows the obtainment of flexible dosages with different shapes, multiple active pharmaceutical ingredients and modulated drug release kinetics-in other words, offering customized medicine. This work aimed to present an update on this technology, discussing its challenges. The co-participation of the pharmaceutical industry and compounding pharmacies seems to be the best way to turn this technology into reality. The pharmaceutical industry can produce drug-loaded filaments on a large scale with the necessary quality and safety guarantees; while digital pharmacies can transform the filaments into personalized medicine according to specific prescriptions. For this to occur, adaptations in commercial 3D printers will need to meet health requirements for drug products preparation, and it will be necessary to make advances in regulatory gaps and discussions on patent protection. Thus, despite the conservatism of the sector, 3D drug printing has the potential to become the biggest technological leap ever seen in the pharmaceutical segment, and according to the most optimistic prognostics, it will soon be within reach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.